Order a test

Helping you make informed decisions and formulate effective treatment plans

More about RGCC

Information for patients

We work with your healthcare provider to deliver a range of personalised tests so you can choose the best treatment together.

More patient information

Stay tuned for RGCC's Cancer App Version 2.0 Coming Soon!

Cancer Tests

New methods and reliable tests to help deliver personalised treatment


RGCC CAMBISeq® is an innovative test that uses next-generation sequencing analysis on both DNA and RNA to provide clinicians with crucial insight into cancer.

View test

Array comparative genomic hybridisation (aCGH) RGCC

The array comparative genomic hybridisation (aCGH) RGCC test is used to identify chromosomal abnormalities in a patient that could lead to cancer.

View test


Immune-Frame is used to assess the condition of a patient’s immune system. Scientists use the test to identify specific cellular markers that are responsible for switching a patient’s immune system on and off.

View test

Metastat RGCC

Metastat RGCC is an advanced test to detect specific blood-borne markers that can accurately determine whether a secondary cancerous tumour is likely to develop and its potential location.

View test


ChemoSNiP is an innovative test that uses an advanced scientific technique called pharmacogenomics to analyse how a patient’s body will respond to a specific drug.

View test

Onconomics Extracts

Onconomics Extracts is a unique and highly detailed test that provides information on how effective natural substances and plants extracts are at attacking circulating cancer cells (CTCs).

View test

Onconomics Plus RGCC

Onconomics Plus RGCC provides information about the effect of specific anti-cancer drugs, targeted therapies and natural treatments on the cancer cells in an individual patient.

View test

Onconomics RGCC

Onconomics RGCC provides highly detailed and accurate information about how effective specific anti-cancer drugs and targeted therapies are in treating cancer.

View test

Oncotrail RGCC

Oncotrail RGCC provides crucial information on the presence of circulating tumour cells (CTCs) and their concentration in patients who have a confirmed diagnosis of specific forms of cancer, including breast, colon and prostate cancer.

View test

Oncotrace RGCC

Oncotrace RGCC is used to identify a primary tumour in a patient and to provide guidance about disease progression and future prognosis.

View test

Oncocount RGCC

Oncocount RGCC detects the presence of circulating tumour cells (CTCs) and their concentration in the blood.

View test
See all RGCC tests

Use our ‘smart filter’ to identify which test is best for your patients

Find out more

News & Events

Find out more about our latest research, trials, and education days.

13th Day of Life Sciences

We are delighted to be one of the main sponsors at the 13th Day of Life Sciences on 9th June 2022. Register for the symposium ‘Competencies in Drug Discovery’ by 7th June, we look forward to seeing you there! Day of Life Sciences | ZHAW Life Sciences and Facility Management

Read more

Genetic mutation could hold the key to new breast cancer treatments

Scientists have identified a mutated gene that causes breast cancer to become more aggressive and spread to other parts of the body in up to 30% of patients. The discovery provides exciting new avenues to develop new treatments for breast cancer, including more effective personalised approaches. Hormone therapy effectively treats around two-thirds of breast cancers, […]

Read more

New immunotherapy target for colon cancer found

German scientists have identified the proteins inside colon cancer cells that trick the immune system from seeing them as a threat. But, in lab tests, once researchers blocked the signals from the cells, the immune systems began to attack them. The insight could help scientists develop new and highly targeted immunotherapies for one of the […]

Read more

New tumour biobank powers personalised cancer treatments

Scientists have discovered new and more effective ways of growing breast cancer tumours that could accelerate research and the development of new treatments. Instead of transplanting human tumours into mice, they’ve developed a bank of “human patient-derived xenografts (PDXs)” that can be used to screen drugs. Used alongside personalised genetic tests could improve cancer treatment […]

Read more

SOTs effective at treating cancer in 77% of patients

Cancer patients treated with the highly targeted supportive oligonucleotide therapy (SOT) showed benefits in 77% of cases, RGCC scientists have found. A new paper published in the in vivo journal finds evidence that SOTs effectively target and kill cancer cells on their own or in tandem with other therapies.  Supportive oligonucleotide therapy is an advanced, […]

Read more

Global Presence

RGCC operates in 23 countries across the world, with bases in all five continents.

Find out more